Elke Pfaff

Publication Activity (10 Years)

Years Active: 2022-2023
Publications (10 Years): 3

Top Topics

Acute Lymphoblastic Leukemia

Epidermal Growth Factor Receptor

Multiple Myeloma

Top Venues

JCO precision oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Anna-Elisa Heipertz, Kristian W Pajtler, Elke Pfaff, Kathrin Schramm, Mirjam Blattner-Johnson, Till Milde, Barbara C Jones, Cecilia Zuliani, Caroline Hutter, Olli Lohi, Antonios Kattamis, Iwona Dachowska-Kalwak, Anna Nilsson, Nicolas U Gerber, Karin P S Langenberg, Bianca Frederika Goemans, Christian Michel Zwaan, Jan J Molenaar, Natalie Jäger, Uta Dirksen, Ruth Witt, Stefan M Pfister, David T W Jones, Dominik T Schneider, Olaf Witt, Cornelis M van Tilburg
Outcome of Children and Adolescents With Relapsed/Refractory/Progressive Malignancies Treated With Molecularly Informed Targeted Drugs in the Pediatric Precision Oncology Registry INFORM. JCO precision oncology 7 (2023)
Anna-Elisa Heipertz, Kristian W Pajtler, Elke Pfaff, Kathrin Schramm, Mirjam Blattner-Johnson, Till Milde, Barbara C Jones, Cecilia Zuliani, Caroline Hutter, Olli Lohi, Antonios Kattamis, Iwona Dachowska-Kalwak, Anna Nilsson, Nicolas U Gerber, Karin P S Langenberg, Bianca Frederika Goemans, Christian Michel Zwaan, Jan J Molenaar, Natalie Jäger, Uta Dirksen, Ruth Witt, Stefan M Pfister, David T W Jones, Dominik T Schneider, Olaf Witt, Cornelis M van Tilburg
Outcome of Children and Adolescents With Relapsed/Refractory/Progressive Malignancies Treated With Molecularly Informed Targeted Drugs in the Pediatric Precision Oncology Registry INFORM. JCO precision oncology 7 (2023)
Elke Pfaff, Tiphaine Adam de Beaumais, Antonin Marchais, Cornelis M van Tilburg, Mirjam Blattner-Johnson, Uta Dirksen, Ingrid Öra, Didier Frappaz, Gudrun Schleiermacher, Stefan M Pfister, Olaf Witt, David T W Jones, Gilles Vassal
NTRK Alterations in Pediatric High-Risk Malignancies Identified Through European Clinical Sequencing Programs Constitute Promising Drug Targets. JCO precision oncology 5 (2022)